Why Oscar Health (OSCR) Is Up 13.1% After Record Q1 Profit Surge And Membership Growth

• In the past week, Oscar Health, Inc. reported first-quarter 2026 results showing revenue of US$4.65 billion and net income of US$679.00 million, with diluted EPS from continuing operations of US$2.07, all sharply higher than a year earlier.
• The quarter also brought record profitability supported by a more than 50% membership increase and improved medical loss and operating margin metrics, while management reaffirmed full-year 2026 guidance and highlighted new initiatives such as the Lucie Health Marketplace and expanded AI use.
• We’ll now examine how this record quarterly profit and membership growth affect Oscar Health’s existing investment narrative and risk outlook.

Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

Oscar Health Investment Narrative Recap

To own Oscar Health today, you need to believe its tech-centric model can turn strong membership growth into durable, disciplined profitability while managing policy and medical cost uncertainty. Q1 2026’s record US$679.00 million net income and 56% membership jump support that case and ease near term worries about margin pressure, but they do not remove the key risk around future regulation and pricing decisions in the ACA individual market.

Among recent moves, the launch of the Lucie Health Marketplace looks most relevant here, because it connects Q1’s membership momentum with a broader product shelf that includes ancillary and employer-funded offerings. If Lucie succeeds in extending Oscar’s reach beyond core individual plans, it could reinforce the current profitability catalyst by diversifying revenue sources, while also partially buffering the business if future ACA-related policy or subsidy changes hurt the individual exchange market.

Yet even with these strong results, investors should still be aware of how regulatory scrutiny of premium hikes could...

Read the full narrative on Oscar Health (it's free!)

Oscar Health's narrative projects $21.6 billion revenue and $649.6 million earnings by 2029. This requires 22.7% yearly revenue growth and a $1.1 billion earnings increase from -$443.2 million.

Uncover how Oscar Health's forecasts yield a $15.40 fair value, a 26% downside to its current price.

Exploring Other Perspectives

The lowest set of analysts tell a much more cautious story, assuming revenue of about US$18.8 billion and earnings of roughly US$500.0 million by 2029, so if you are weighing Q1’s record profit against worries about premium approvals and cost inflation, it is worth remembering that informed opinions differ widely and may shift again as this new data is absorbed.

Explore 19 other fair value estimates on Oscar Health - why the stock might be worth 45% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Oscar Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Oscar Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oscar Health's overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com